Current treatments for endometriosis are unsuitable for women who wish to conceive. To verify the supposed beneficial effects of Graptophyllum pictum (G. pictum) on reproductive diseases and inflammation, endometriosis was …
Activated eosinophil plays a role in promoting fibrosis in endometriotic lesion Nature
The fibrosis mechanism in endometriosis is not elucidated. We investigated the role of eosinophil in fibrosis of endometriosis. The endometriotic stromal cells (ESCs) and endometrial epithelial cells (EECs) were subjected …
This study aimed to evaluate the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and mucinous borderline tumors (MBTs) and to establish a diagnostic approach using immunohistochemistry (IHC) and Alcian …
Evidence regarding risk for hysterectomy following treatment for benign gynecological conditions with a Levonorgestrel-releasing intrauterine device (LNG-IUD) is limited. We assess whether race and ethnicity are associated with hysterectomy risk …
Endometriosis is a prevalent, complex, inflammatory condition associated with a diverse range of symptoms and comorbidities. Despite its substantial burden on patients, population-level studies that explore its comorbid patterns and …
Comparison of the Efficacy of Single vs. Double Autologous Platelet-Rich Plasma (PRP) Intrauterine Infusion on Endometrial Receptivity in Thin Endometrium Patients: A Prospective Randomized Controlled Trial Frontiers
To test, among women with natural menopause, whether: infertility, miscarriage, stillbirth, and low parity are associated with a higher risk of osteoporosis; menopause age can partly explain their associations.
In this study, we aimed to investigate whether serum NGAL, MMP-9 and the MMP-9/NGAL ratio, which are inflammatory markers used for the diagnosis and follow-up of some diseases, can be …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …